---
title: "Harrow says QUELL trial of IHEEZO posts topline data in Q4 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293204227.md"
description: "Harrow Inc. presented new clinical and real-world evidence for IHEEZO and BYOOVIZ at the ASRS 2026 meeting. Interim results suggest IHEEZO improves patient comfort compared to common anesthetics, with no increased infection risk signal observed in a retrospective review. The QUELL trial remains ongoing, with topline data expected in Q4 2026. Additionally, interim findings from a post-marketing surveillance study of BYOOVIZ were shared."
datetime: "2026-07-20T11:07:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293204227.md)
  - [en](https://longbridge.com/en/news/293204227.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293204227.md)
generator: "portal-rs"
---

# Harrow says QUELL trial of IHEEZO posts topline data in Q4 2026

-   Harrow highlighted new clinical and real-world evidence for IHEEZO and BYOOVIZ presented at the ASRS 2026 annual meeting. \* Interim results from a randomized study suggested IHEEZO could improve post-injection comfort and overall patient experience versus a common anesthetic approach. \* A large retrospective review found no signal that IHEEZO’s gel formulation increased infection risk when used with a chlorhexidine-based antisepsis routine. \* The QUELL randomized, multi-center trial remains ongoing, with topline results expected in Q4 2026. \* Interim findings from a large real-world post-marketing surveillance study of BYOOVIZ were also presented at the meeting. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harrow Inc. published the original content used to generate this news brief on July 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [HROW.US](https://longbridge.com/en/quote/HROW.US.md)
- [HROWM.US](https://longbridge.com/en/quote/HROWM.US.md)
- [HROWL.US](https://longbridge.com/en/quote/HROWL.US.md)

## Related News & Research

- [Harrow CFO Andrew Boll takes on principal accounting officer role after Pollard exit](https://longbridge.com/en/news/298074705.md)
- [Harrow says IHEEZO trial shows 58% lower discomfort than proparacaine after intravitreal injections](https://longbridge.com/en/news/296478792.md)
- [HF Sinclair announces Q3 2026 dividend of R$ 1.81 per unit](https://longbridge.com/en/news/298317474.md)
- [PETROBRAS updates financial events calendar for 2026](https://longbridge.com/en/news/298078546.md)
- [Essex Property Trust declares Q3 2026 dividend of R$ 0.89 per unit](https://longbridge.com/en/news/298322539.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**